Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]3F4AP PET Imaging in TBI and Neurodegeneration
NCT04710550Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of F-18 3F4AP (4 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Number of participants with treatment-related adverse events at 5 years. Started Jan 2021; status: active, not recruiting.
02
Drugs
F-18 3F4AP
Beyond the preview
Go deeper on NCT04710550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710550.